Drug intelligence / Profile preview

DEC003M

Development stage: Phase 1
Lead developer: Hangzhou DAC Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DEC003M is an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), developed by Hangzhou DAC Biotech. It is currently in Phase I clinical development for the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). The therapeutic is designed to deliver a cytotoxic payload directly to PSMA-expressing tumor cells, minimizing systemic toxicity. The ongoing first-in-human study (CTR20262361) evaluates the safety, tolerability, and preliminary efficacy of DEC003M monotherapy administered intravenously every three weeks in patients who have failed standard treatments, including novel hormonal agents.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on DEC003M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DEC003M.

Explore the full profile